A year after losing its big pharma partner, epigenetic cancer therapy-focused Epizyme Inc. used its quarterly earnings call on March 9 to outline a four-step strategy for becoming a commercial company, expanding the potential uses for lead candidate tazemetostat (EPZ-6438, aka taz) and bringing at least three novel proprietary cancer candidates into clinical development by 2020.
Central to this strategy is a plan to seek expedited approval of tazemetostat based on findings from Phase II studies...
